What Is the Best Injection for Weight Loss at Home? A 2026 Comparison of Available Options

Key Takeaways

• Tirzepatide (Zepbound, Mounjaro, or compounded) produces the largest documented weight loss in published trials, averaging 20.9% of body weight over 72 weeks at 15 mg in SURMOUNT-1.
• Semaglutide (Wegovy, Ozempic, or compounded) is the next strongest with an average 14.9% body-weight reduction at 2.4 mg over 68 weeks in STEP 1.
• Both are self-injected once weekly under the skin (subcutaneous), typically in the abdomen, thigh, or upper arm.
• Liraglutide (Saxenda) requires daily injection and produces less weight loss (about 8% over 56 weeks).
• The "best" injection depends on tolerability, insurance coverage, cost, and clinical fit, not on a single ranking.

Direct answer (40-60 words)

The best at-home weight-loss injections in 2026 are tirzepatide (sold as Zepbound for weight loss or as compounded tirzepatide) and semaglutide (Wegovy or compounded). Tirzepatide produces the largest weight loss in published trials, around 20.9% body weight at the highest dose. Both are self-injected weekly using a pen or U-100 insulin syringe.

Table of contents

1. The 30-second answer
2. The 4 weight-loss injections available for home use
3. Head-to-head trial data: how much weight each one takes off
4. How injection frequency and method differ
5. Side effects: what to expect at home
6. Cost ranges in 2026
7. Who shouldn't use weight-loss injections
8. How to inject safely at home: a 9-step protocol
9. Choosing between brand-name pen and compounded vial
10. Where weight-loss injections fit in a broader plan
11. FAQ
12. Sources
13. Footer disclaimers

The 4 weight-loss injections available for home use

Four injectable medications are FDA-approved or commonly prescribed for chronic weight management as of 2026.

Tirzepatide (Zepbound). Dual GLP-1 / GIP receptor agonist. Once-weekly injection. Doses titrated from 2.5 mg to 15 mg over 16 to 20 weeks. FDA-approved for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity. The same molecule is sold as Mounjaro for type 2 diabetes.

Semaglutide (Wegovy). GLP-1 receptor agonist. Once-weekly injection. Doses titrated from 0.25 mg to 2.4 mg over 16 to 20 weeks. FDA-approved for chronic weight management with the same BMI criteria as Zepbound. The same molecule is sold as Ozempic for type 2 diabetes.

Liraglutide (Saxenda). Older-generation GLP-1 agonist. Daily injection. Doses titrated from 0.6 mg to 3.0 mg. FDA-approved for chronic weight management. Becoming less common as weekly tirzepatide and semaglutide produce more weight loss with less injection burden.

Compounded GLP-1 medications. Compounded semaglutide and tirzepatide prepared by 503A licensed compounding pharmacies. Drawn from a multi-dose vial with a U-100 insulin syringe. Not FDA-approved. Not interchangeable with brand-name pens. Available through some telehealth platforms and local compounding pharmacies, generally at lower monthly cost than brand-name pens.

A handful of older anti-obesity injections (e.g., Wegovy's predecessor Saxenda) are still occasionally prescribed but produce less weight loss and aren't typically what patients mean when they ask about "the best injection."

Head-to-head trial data: how much weight each one takes off

The most useful way to compare weight-loss injections is the average percentage of body weight lost in published Phase 3 trials.

Medication	Trial	Maximum dose	Duration	Average weight loss
Tirzepatide	SURMOUNT-1 (Jastreboff et al., NEJM 2022)	15 mg weekly	72 weeks	20.9%
Tirzepatide	SURMOUNT-1	10 mg weekly	72 weeks	19.5%
Tirzepatide	SURMOUNT-1	5 mg weekly	72 weeks	15.0%
Semaglutide	STEP 1 (Wilding et al., NEJM 2021)	2.4 mg weekly	68 weeks	14.9%
Semaglutide	STEP 5 (Garvey et al., Nat Med 2022)	2.4 mg weekly	104 weeks	15.2%
Tirzepatide	SURMOUNT-3 (Wadden et al., Nat Med 2023)	15 mg weekly + intensive lifestyle	72 weeks	26.6%
Liraglutide	SCALE (Pi-Sunyer et al., NEJM 2015)	3.0 mg daily	56 weeks	8.0%

A direct head-to-head trial published in 2024, SURMOUNT-5 (Aronne et al., NEJM 2024), compared tirzepatide and semaglutide at maximum doses for 72 weeks. Tirzepatide produced 20.2% weight loss; semaglutide produced 13.7%. The 6.5 percentage-point difference is the strongest current evidence that tirzepatide is the more potent option for raw weight reduction.

What this doesn't tell you:

• Side effect tolerability varies. Some patients tolerate semaglutide better than tirzepatide and end up losing more on the medication they can stay on.
• Maintenance differs from initial loss. STEP 4 (Rubino et al., JAMA 2021) showed that stopping semaglutide leads to ~two-thirds weight regain over 68 weeks. Maintenance studies on tirzepatide (Aronne et al., 2024 SURMOUNT-4) showed similar regain when discontinued.
• Real-world results are typically lower than trial results because trial patients have higher adherence and more support.

How injection frequency and method differ

The injection technique varies meaningfully between the options.

Medication	Frequency	Method	Needle
Zepbound	Weekly	Pre-filled single-dose pen	Internal needle, no separate needle attachment
Wegovy	Weekly	Pre-filled multi-use pen	Replaceable pen needle (32g, 4 mm)
Saxenda	Daily	Pre-filled multi-use pen	Replaceable pen needle (32g, 4 mm)
Compounded semaglutide	Weekly	Multi-dose vial with U-100 syringe	31g, 5/16 inch (0.3 or 0.5 mL syringe)
Compounded tirzepatide	Weekly	Multi-dose vial with U-100 syringe	31g, 5/16 inch (0.3 or 0.5 mL syringe)

Pen formats are simpler for new injectors. The dose dial sets the amount, and the pen mechanism delivers it without measuring. Vial formats require drawing the dose with a syringe, which adds a step but allows finer dose control during titration.

The injection itself is subcutaneous (under the skin, not into muscle). Standard sites are the abdomen (avoid 2 inches around the navel), the front or outer thigh, and the back of the upper arm. Sites should be rotated weekly to prevent lipohypertrophy.

Side effects: what to expect at home

The dominant side effects across all GLP-1 receptor agonists are gastrointestinal.

Common (10% or more of patients):

• Nausea, especially during titration
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain
• Decreased appetite (this is the therapeutic effect, but at the extreme it can be uncomfortable)

Less common (1 to 10%):

• Acid reflux and heartburn
• Bloating
• Belching
• Injection-site reactions (redness, itching)
• Fatigue
• Dizziness

Rare but serious:

• Pancreatitis (severe upper-abdominal pain that radiates to the back)
• Gallbladder disease, including gallstones requiring surgery
• Severe gastroparesis or ileus
• Hypoglycemia (mainly in patients also on insulin or sulfonylureas)
• Acute kidney injury, typically from severe dehydration during persistent vomiting
• Allergic reactions

Tirzepatide and semaglutide have similar GI side effect profiles. SURMOUNT-5 found tirzepatide had slightly higher rates of nausea (44.2% vs 35.2%) and vomiting (24.7% vs 18.0%), but discontinuation rates due to side effects were comparable.

Liraglutide produces similar side effects but with daily exposure, so the cumulative GI burden is sometimes harder to tolerate.

For acid reflux specifically (a common Zepbound side effect), see our Zepbound and acid reflux protocol.

Cost ranges in 2026

Pricing varies dramatically based on insurance coverage, savings cards, and pharmacy choice.

Brand-name pen prices (cash, no insurance):

• Zepbound: $1,060 to $1,200 per month at retail pharmacies
• Zepbound vials via LillyDirect: $349 to $549 per month
• Wegovy: $1,300 to $1,400 per month at retail pharmacies
• Saxenda: $1,300 to $1,400 per month at retail pharmacies

Brand-name pen prices (with insurance + savings card):

• Zepbound: $25 to $250 per month, plus $25 with Eli Lilly savings card if eligible
• Wegovy: $25 to $250 per month, plus $0 to $25 with Novo Nordisk savings card if eligible
• Saxenda: $25 to $250 per month with savings programs

Compounded medications via telehealth:

• Compounded semaglutide: $179 to $279 per month
• Compounded tirzepatide: $199 to $499 per month

The compounded pricing has tightened since FDA's 2024 to 2025 guidance on compounded GLP-1s, but it remains the most affordable path for uninsured patients in many markets.

For more on compounded semaglutide's specific pricing, see our compounded semaglutide cost guide.

Who shouldn't use weight-loss injections

GLP-1 receptor agonists aren't appropriate for everyone. The contraindications and cautions:

Absolute contraindications (don't use):

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Pregnancy or active breastfeeding
• Hypersensitivity to the active ingredient

Cautions (use with provider judgment):

• History of pancreatitis
• Severe gastroparesis (pre-existing)
• Severe kidney impairment
• Active gallbladder disease
• History of suicidal ideation (FDA continues to monitor; current data does not require label warnings)
• Eating disorders, particularly restrictive disorders

Drug interactions:

• Insulin and sulfonylureas (hypoglycemia risk; may need dose adjustment)
• Oral medications with narrow absorption windows (delayed gastric emptying can affect timing)
• Oral contraceptives (some evidence of reduced effectiveness during the first 4 weeks of tirzepatide; barrier method recommended during titration)

Anyone considering a weight-loss injection should have a thorough medical evaluation by a licensed provider. Telehealth platforms can do this remotely, but they cannot prescribe responsibly without a complete history.

How to inject safely at home: a 9-step protocol

The basic injection protocol is the same across pens and vials with minor format-specific adjustments.

Materials:

• The medication (pen or vial)
• For vial: a U-100 insulin syringe (31-gauge, 5/16-inch, 0.3 or 0.5 mL barrel)
• Two alcohol swabs
• A sharps container

Steps:

1. Wash your hands with soap and water for 20 seconds.
2. Take the medication out of the fridge 15 to 30 minutes before injection. Cold injections are more painful and the medication flows more slowly.
3. Inspect the medication. It should be clear and colorless to faintly straw-yellow. If it's cloudy, has visible particles, or has changed color unexpectedly, don't use it. Contact the pharmacy.
4. For pens: attach a new pen needle. For vials: wipe the rubber stopper with an alcohol swab, draw your prescribed dose into the syringe, check for air bubbles.
5. Choose an injection site. Abdomen (avoiding 2 inches around the navel), front or outer thigh, or back of upper arm. Rotate sites weekly.
6. Wipe the site with the second alcohol swab. Let it air-dry. Don't blow on it.
7. Pinch a fold of skin. Insert the needle perpendicular to the skin (or 45 degrees if you have very little subcutaneous fat). Push the dose button on a pen or push the syringe plunger steadily.
8. Hold the pen against the skin for 6 seconds after the dose-window reads zero (manufacturer requirement for full delivery on most pens). For syringe injection, withdraw immediately after delivering the full dose.
9. Dispose of the pen needle or syringe in a sharps container. Don't recap.

If the dose draws are unfamiliar (especially for compounded vials), a unit-conversion chart helps. Our tirzepatide units guide covers conversion at every common concentration.

The whole process takes 60 to 90 seconds once you've done it a few times.

Choosing between brand-name pen and compounded vial

The trade-offs:

Brand-name pen advantages:

• Pre-measured doses, no draw step
• FDA-approved manufacturing standards
• Established stability and labeling
• Pharmacy support if a pen malfunctions
• Insurance coverage often available

Brand-name pen drawbacks:

• Higher cost without insurance
• Pen-supply shortages have been recurrent (less so in 2026)
• Fixed dose increments don't allow fine titration

Compounded vial advantages:

• Lower monthly cost in many markets
• Finer dose control during titration
• Consistent supply through compounding pharmacies
• Predictable monthly pricing without insurance paperwork

Compounded vial drawbacks:

• Not FDA-approved
• Not interchangeable with brand-name products
• Quality varies by compounding pharmacy
• Requires drawing dose with a syringe (more steps)
• Less established long-term data on specific compounded preparations
• FDA's 2024 to 2025 guidance restricts which formulations are permissible

Patients with strong insurance coverage often default to brand-name. Patients without coverage or with high copays often choose compounded.

The "best" choice is patient-specific and should be made with a licensed provider. Both produce weight loss when the dose, frequency, and adherence match published protocols.

Where weight-loss injections fit in a broader plan

Weight-loss injections work best as one piece of a multi-component plan. The trial data underlines this. SURMOUNT-3 (intensive lifestyle plus tirzepatide) produced 26.6% weight loss vs SURMOUNT-1's 20.9% with standard lifestyle counseling.

The components that strengthen injection-based weight loss:

Protein intake. A 2024 meta-analysis (Heymsfield et al., 2024) found GLP-1 patients meeting 1.2 to 1.6 g/kg/day of protein retained more lean mass than those on lower intake. Lean mass preservation improves long-term metabolic health and reduces regain.

Resistance training. Two to three sessions per week reduces lean-mass loss and improves body composition. The American College of Sports Medicine recommends progressive resistance training during caloric deficit periods.

Behavioral support. Weekly check-ins, food logging, or telehealth coaching improves adherence and outcomes. Most successful patients in the trials had structured support.

Sleep and stress management. Sleep-deprived patients have elevated ghrelin and reduced leptin, which can blunt appetite suppression. Cortisol elevation from chronic stress promotes visceral fat retention.

Realistic expectations on duration. Weight regain is the rule, not the exception, after stopping a GLP-1 medication. Patients who plan for indefinite use (or have a structured maintenance plan including ongoing low-dose medication) have better long-term outcomes than those who view the injection as a 6-month intervention.

FAQ

What is the best injection for weight loss at home?

Tirzepatide (Zepbound or compounded) produces the largest documented weight loss, averaging 20.9% of body weight at 15 mg over 72 weeks in SURMOUNT-1. Semaglutide (Wegovy or compounded) is the second-strongest at 14.9% at 2.4 mg over 68 weeks. Both are self-injected weekly.

Which is better, semaglutide or tirzepatide for weight loss?

Tirzepatide produces more weight loss in head-to-head data (SURMOUNT-5: 20.2% vs 13.7% over 72 weeks). Tirzepatide also has slightly higher rates of nausea and vomiting. Patient choice often comes down to insurance coverage, tolerability, and cost rather than raw potency.

How often do you inject weight-loss medication at home?

Tirzepatide and semaglutide are once-weekly injections. Liraglutide is daily. Most patients pick a consistent day of the week (e.g., every Sunday) to keep the timing predictable. Pens and vials are self-injected subcutaneously in the abdomen, thigh, or upper arm.

Where do you inject weight-loss medication?

Three subcutaneous sites: the abdomen (avoiding 2 inches around the navel), the front or outer thigh, or the back of the upper arm. Rotate sites weekly to prevent lipohypertrophy (fatty tissue thickening that reduces absorption).

Can you self-inject weight-loss medication at home safely?

Yes, with proper training. Both pens and vials are designed for at-home self-injection. The needle is short (4 to 8 mm) and fine (31 to 32 gauge). Most patients describe the injection as a brief sting or no sensation at all. Provider walk-throughs and online video demonstrations are standard.

How much weight will I lose on injection medication?

Trial averages: 20.9% on tirzepatide 15 mg over 72 weeks (SURMOUNT-1), 14.9% on semaglutide 2.4 mg over 68 weeks (STEP 1), 8.0% on liraglutide 3.0 mg over 56 weeks (SCALE). Real-world results are usually somewhat lower because adherence is lower outside trial conditions.

Are at-home weight-loss injections safe?

For appropriately selected patients, yes. The published trials show favorable benefit-risk profiles. Side effects are common but usually GI and resolvable. Rare serious risks include pancreatitis, gallbladder disease, and severe gastroparesis. A complete medical evaluation before starting is essential.

How long do you need to take weight-loss injections?

GLP-1 medications are generally considered chronic treatment. STEP 4 (Rubino et al., JAMA 2021) showed weight regain of about two-thirds of lost weight over 68 weeks after semaglutide discontinuation. Most patients who maintain results take the medication indefinitely or transition to a maintenance dose.

Do at-home weight-loss injections work without diet and exercise?

The medications produce weight loss even without intensive lifestyle changes, but they work better with both. SURMOUNT-3 (Wadden et al., Nat Med 2023) showed 26.6% weight loss with intensive lifestyle plus tirzepatide vs 20.9% in SURMOUNT-1's standard lifestyle counseling.

What's the difference between Ozempic and Zepbound for weight loss?

Ozempic (semaglutide) is FDA-approved for type 2 diabetes, not weight loss. Wegovy is the same molecule approved for weight loss. Zepbound (tirzepatide) is FDA-approved for weight loss; Mounjaro is the same molecule for diabetes. Insurance coverage rules differ by indication.

Are compounded weight-loss injections safe?

Compounded semaglutide and tirzepatide can be a reasonable alternative for some patients. They are not FDA-approved and not interchangeable with brand-name products. Quality depends on the compounding pharmacy. Working with a licensed provider through a reputable telehealth platform reduces risk.

How fast do weight-loss injections start working?

Appetite suppression often begins within 1 to 2 weeks. Measurable weight loss typically appears by week 4 to 6. The full effect builds gradually as doses titrate up over 16 to 20 weeks. Plateau weight loss is achieved over 56 to 72 weeks in trial settings.

Sources

1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
2. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
3. Aronne LJ, et al. Tirzepatide vs Semaglutide for Weight Loss (SURMOUNT-5). N Engl J Med. 2024.
4. Wadden TA, et al. Tirzepatide With Intensive Lifestyle Intervention (SURMOUNT-3). Nat Med. 2023.
5. Garvey WT, et al. Two-Year Effects of Semaglutide on Body Weight (STEP 5). Nat Med. 2022;28:2083-2091.
6. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414-1425.
7. Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). N Engl J Med. 2015;373:11-22.
8. Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024.
9. Heymsfield SB, et al. Lean Mass Preservation During GLP-1 Receptor Agonist Therapy: A Meta-Analysis. Obesity. 2024.
10. American College of Sports Medicine Position Stand on Resistance Training and Body Composition, 2023.
11. U.S. Food and Drug Administration. Zepbound, Wegovy, Saxenda Prescribing Information, 2024 to 2026 revisions.
12. U.S. FDA Guidance on Compounded GLP-1 Drug Products, 2025.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic, and Saxenda are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.